Sacubitril/valsartan cannot improve cardiac function compared with valsartan in patients suffering nonvalvular atrial fibrillation without systolic heart failure

Author:

Zhu Mingxin1,Guo Jianfeng1,qiqike Badeng2,nay Xeri2,dan Shan2,Kuransi Aidina2,Hu Gaokai2,Han Zhangtong2,Hou Dong2,aili Ailifeilai2,Xia Bin2,Chen Ping2,bate Bayin2,Xie Jiangjiao1

Affiliation:

1. Union Hospital, Huazhong University of Science and Technology

2. People’s hospital, Mongolian Autonomous prefecture of Bortala

Abstract

Abstract Background: The aim of this study was to investigate the effect of Sacubitril/valsartan (Sac/Val) in patients diagnosed with nonvalvular atrial fibrillation (AF) without systolic heart failure (SHF). Methods: Nonvalvular AF patients without SHF admitted to the People’s Hospital of Boltala Mongolian Autonomous Prefecture from December 2020 to December 2021 were enrolled and randomly divided into the Sac/Val treatment group (group T) and valsartan treatment group (group C, control). For subgroup analysis, patients were divided into subgroups with and without diastolic heart failure (DHF). After a 1-month run-in period and subsequent 3-month treatment period, patients were followed up in the cardiology clinic. Plasma levels of biochemical markers and echocardiographic parameters before and after treatment were compared, and DHF scores were calculated for comparison of diastolic function. Results: Of 61 enrolled patients, 46 patients completed the follow-up. Sac/Val treatment did not increase the proportion of sinus rhythm. Although NT-proBNP expression tended to be reduced in both groups after 3 months of treatment, the differences compared with respective baseline levels and between groups were not significant. Subgroup analysis suggested that NT-proBNP expression in the subgroup with DHF was decreased at follow-up versus baseline, but the difference was not significant. Similarly, no marked differences in echocardiographic parameters or tissue Doppler parameters related to DHF were detected between the groups (P>0.05). Subgroup analysis also showed no significant differences in the echocardiographic parameters between subgroups (P>0.05). Conclusion: Sac/Val is not superior to valsartan in the treatment for patients suffering with AF without SHF.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3